Which class of antidiabetic medication has demonstrated cardiovascular benefits in heart failure with reduced ejection fraction?

• A. Metformin
• B. GLP-1 receptor agonists
• C. DPP-4 inhibitors
• D. SGLT2 inhibitors

Answer: (D)

SGLT2 inhibitors provide cardiovascular benefits in heart failure with reduced ejection fraction beyond just lowering blood glucose. In major trials like DAPA-HF and EMPEROR-Reduced, these drugs reduced the composite of cardiovascular death and heart failure hospitalization by about 25–30%, and importantly, the benefit was seen regardless of whether patients had diabetes. They also showed renal protective effects, which helps slow progression of kidney disease often coexisting with heart failure.

Mechanistically, the advantages come from several actions: osmotic diuresis and natriuresis reduce preload and edema; modest blood pressure and weight benefits lower cardiac workload; improved renal hemodynamics helps maintain fluid balance; shifts in myocardial energy utilization and anti-inflammatory/fibrotic effects may enhance heart muscle function over time. The combination of hemodynamic and metabolic improvements translates into fewer heart failure events and better survival.

Other antidiabetic classes have less consistent evidence for improving heart failure outcomes. GLP-1 receptor agonists mainly reduce atherosclerotic cardiovascular events with less clear impact on heart failure outcomes. DPP-4 inhibitors have largely neutral effects on heart failure, with some concerns about increased hospitalization in certain trials. Metformin’s cardiovascular benefits in heart failure are not as robust or established for reducing heart failure–related events.

Thus, the class that has demonstrated cardiovascular benefits in heart failure with reduced ejection fraction is the SGLT2 inhibitors.